

REFERENCES/LIVER HEALTH

1. Zeisel, S. H., & da Costa, K. A. (2009). Choline: An essential nutrient for public health. *Nutrition Reviews*, 67(11), 615-623.
2. Mara Sophie Vell, Kate Townsend Creasy, Scorletti, E., Katharina Sophie Seeling, Hehl, L., Miriam Daphne Rendel, Kai Markus Schneider and Schneider, C.V. (2023). Omega-3 intake is associated with liver disease protection. *Frontiers in Public Health*, [online] 11. doi:<https://doi.org/10.3389/fpubh.2023.1192099>.
3. Loguercio, C., & Festi, D. (2011). Silybin and the liver: From basic research to clinical practice.
4. Panahi, Y., et al. (2019). Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease.
5. Mouzaki, M., & Allard, J. P. (2019). The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease.

REFERENCES/PROBIOTIC

- 1,8: McKinsey & Company (2024). What's new in consumer wellness trends? | McKinsey. [online] www.mckinsey.com. Available at: <https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/whats-new-in-consumer-wellness-trends>.
- 2: Hill C, Guarner F, Reid G, et al. (2014). The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*, 11(8), 506–514.
- 3,6: Food Standards Europe Probiotic Report April 2021
- 4: Cleveland Clinic (2024). What Is Gut Dysbiosis? [online] Cleveland Clinic. Available at: <https://my.clevelandclinic.org/health/diseases/dysbiosis>.
- 5,7: Lohr, A.A. and Jackson, C. (2023). Most Americans are uninformed about gut health and the microbiome. [online] Ipsos. Available at: <https://www.ipsos.com/en-us/most-americans-are-uninformed-about-gut-health-and-microbiome>.
- 9: Market.U.S (2023). Probiotic Market Size is Expected to Reach USD 131 Bn by 2032; Food and Beverage Industry Drives the Growth. [online] GlobeNewswire News Room. Available at: <https://www.globenewswire.com/en/news-release/2023/03/16/2628961/0/en/Probiotic-Market-Size-is-Expected-to-Rreach-USD-131-Bn-by-2032-Food-and-Beverage-Industry-Drives-the-Growth.html>.
- 10,11: Fu, J., Bonder, M.J., Cenit, M.C., Tigchelaar, E.F., Maatman, A., Dekens, J.A.M., Brandsma, E., Marczyńska, J., Imhann, F., Weersma, R.K., Franke, L., Poon, T.W., Xavier, R.J., Gevers, D., Hofker, M.H., Wijmenga, C. and Zhernakova, A. (2015). The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids. *Circulation Research*, 117(9), pp.817–824. doi:<https://doi.org/10.1161/circresaha.115.306807>.
- 12: Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., DuGar, B., Feldstein, A.E., Britt, E.B., Fu, X., Chung, Y.-M., Wu, Y., Schauer, P., Smith, J.D., Allayee, H., Tang, W.H.W., DiDonato, J.A., Lusis, A.J. and Hazen, S.L. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature*, 472(7341), pp.57–63. doi:<https://doi.org/10.1038/nature09922>.
- 13: Zhu, W., Wang, Z., Tang, W.H.W. and Hazen, S.L. (2017). Gut Microbe-Generated Trimethylamine N -Oxide From Dietary Choline Is Prothrombotic in Subjects. *Circulation*, 135(17), pp.1671–1673. doi:<https://doi.org/10.1161/circulationaha.116.025338>.
- 14: Robertson, R. (2017). Why the Gut Microbiome Is Crucial for Your Health. [online] Healthline. Available at: https://www.healthline.com/nutrition/gut-microbiome-and-health#TOC_TITLE_HDR_6.
- 15: Metchnikoff, E (1907) The prolongation of life: optimistic studies
- 16: Reed, C. (2020). AGA does not recommend the use of probiotics for most digestive conditions. [online] American Gastroenterological Association. Available at: <https://gastro.org/news/aga-does-not-recommend-the-use-of-probiotics-for-most-digestive-conditions-2/>.
- 17,18: Qu, S., Yu, Z., Zhou, Y., Wang, S., Jia, M., Chen, T. and Zhang, X. (2024). Gut microbiota modulates neurotransmitter and gut-brain signaling. *Microbiological Research*, 287, p.127858. doi:<https://doi.org/10.1016/j.micres.2024.127858>.
- 19: Mosca, L., Benjamin, E.J., Berra, K., Bezanson, J.L., Dolor, R.J., Lloyd-Jones, D.M., Newby, L.K., Piña, I.L., Roger, V.L., Shaw, L.J., Zhao, D., Beckie, T.M., Bushnell, C., D'Armiento, J., Kris-Etherton, P.M., Fang, J., Ganiats, T.G., Gomes, A.S., Gracia, C.R. and Haan, C.K. (2011). Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update. *Circulation*, 123(11), pp.1243–1262. doi:<https://doi.org/10.1161/cir.0b013e31820faaf8>.
- 20: Currie, H. and Williams, C. (2008). Menopause, Cholesterol and Cardiovascular Disease | USC Journal. [online] www.uscjournal.com. Available at: <https://www.uscjournal.com/articles/menopause-cholesterol-and-cardiovascular-disease-0>.
- 21: Schnatz, P.F. and Schnatz, J.D. (2006). Dyslipidemia in Menopause: Mechanisms and Management. *Obstetrical & Gynecological Survey*, 61(9), pp.608–613. doi:<https://doi.org/10.1097/01.ogx.0000235502.95332.54>.
- 22: Williams, C.M. (2004). Lipid metabolism in women. *Proceedings of the Nutrition Society*, [online] 63(1), pp.153–160. doi:<https://doi.org/10.1079/pns2003314>.
- 23: Rosano, G.M.C., Vitale, C., Marazzi, G. and Volterrani, M. (2007). Menopause and cardiovascular disease: the evidence. *Climacteric*, 10(sup1), pp.19–24. doi:<https://doi.org/10.1080/13697130601114917>.
- 24: Jackson, G. (2008). Gender differences in cardiovascular disease prevention. *Menopause International*, 14(1), pp.13–17. doi:<https://doi.org/10.1258/mi.2007.007031>.